<DOC>
	<DOC>NCT02278146</DOC>
	<brief_summary>A multi-center, open-label, prospective, feasibility study evaluating the ParaPatch System for the treatment of urinary incontinence and overactive bladder.</brief_summary>
	<brief_title>Feasibility Study Evaluating the ParaPatch System</brief_title>
	<detailed_description>- Baseline Period o The baseline period will allow for washout of any medication affecting bladder function and to allow subject to begin her voiding diary. - Prospective data collection will take place in the form voiding diary. Leak frequency, and other relevant parameters will be collected. - Inclusion/exclusion criteria will be rechecked at end of baseline. - Qol questionnaires will be completed in the office at the end of baseline period. - Evaluation Period o During the evaluation period, the subjects will use the ParaPatch System. - No medications affecting bladder function will be allowed during the evaluation period. - Subjects will complete voiding diaries, during the evaluation period. Data capture to include: adverse events, medication use, leak frequency and other relevant parameters. - Qol questionnaires will be completed in the office at the end of evaluation period. - Follow-up Period o Subjects will be followed for after the evaluation period to check for residual Adverse Events. - No medications affecting bladder function will be allowed during the follow-up period. - Subjects will be called by the clinical coordinator at the end of the Follow-up period and asked about potential Adverse Events.</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<criteria>Women aged from &gt;18 to &lt; 75 years old. Subject has the ability to read and comprehend English, and to reliably record information as required by the Protocol, including the proper completion of the questionnaires. Subject is able to provide written informed consent prior to participation in the study. Diagnosed with either of the following: a) overactive bladder, or b) urinary stress incontinence. Are currently participating or have participated within the past 30 days in any clinical investigation involving or impacting urinary or renal function. Subject has demonstrated or is believed to be at risk of noncompliance with study procedures (e.g., for completing the diary or returning for required followup visits). Subject has undergone onabotulinumtoxinA injections of the bladder in the last twelve (12) months. Subject is not suitable for the study for any reason (including overall health, preexisting conditions or medications) in the judgment of the investigator. Have an untreated recurrent urinary tract infection (&gt; 2 times within the past 6 months). Have neurogenic disorders such as Multiple Sclerosis, ALS, or Parkinson s Disease. Patients with a diagnosis of painful bladder syndrome, other pelvic pain or interstitial cystitis.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>